A pharmacovigilance analysis of carbapenem-related utilizing the FDA adverse event reporting system (FAERS) database from 2013 to 2025 - PubMed
a day ago
- #pharmacovigilance
- #haematologic safety
- #carbapenems
- Pharmacovigilance analysis of carbapenem-related adverse events using FAERS database (2013-2025).
- Meropenem showed the most extensive toxicity profile with 15 adverse events, including severe conditions like thrombocytosis and bone marrow failure.
- Imipenem demonstrated signals for nine adverse events, notably thrombocytopenia and eosinophilia.
- Ertapenem was associated with nine events, including leucopenia and neutropenia.
- No reports of haematologic adverse events were identified for doripenem.
- Significant differences in haematologic safety profiles among carbapenems were found, with meropenem showing the broadest spectrum of severe toxicity.
- The findings suggest the need for careful carbapenem selection, especially in patients with baseline haematologic disorders.